Newsbenzinga
Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
· Published
Article summary
Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and reduced near-term re-rating potential.
An excerpt from the original article.
Comments —
Loading comments…